
Kopra Bio
Kopra Bio is a YC Summer 2024 (S24) company. Based in San Francisco, CA, USA. Team of 2.
About Kopra Bio
Summary
Kopra Bio develops genetically engineered viruses that train the immune system to attack cancer cells. The therapy reprograms cancer cells themselves to produce the signals that drive their own destruction, replacing conventional immunotherapy drugs. The company is targeting glioblastoma, the most aggressive form of brain cancer, first.
Go-to-market
The company is in the preclinical stage, advancing a pipeline built on UCSF-developed technology toward therapeutic candidates for oncology.
From the Y Combinator listing
Genetically engineered viruses that teach your immune system to kill…
Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.
Facts
- Healthcare / Healthcare -> Therapeutics
- San Francisco, CA, USA
- 2
- Active
- Early
Founders (1)
- Alexander Haddad
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works